| **Author, year** | **Group1** | **Group2** | **Outcome (definition)** | **AE collection / ITT** | **Results, Group 1** | **Results, Group 2** |
| --- | --- | --- | --- | --- | --- | --- |
| Reinisch, 2010188 | Azathioprine  Route: Oral  Dose: 2.0-2.5 mg/kg every 1 days | Mesalamine (Salofalk)  Route: Oral  Dose: 4 g every 1 days | HR QoL (IBDQ) @ 52 weeks | NA  Yes | F-B: Mean, 9 (SD, 17.7)  G1-G2: -4 | F-B: Mean, 5 (SD, 27.4) P: 0.4565  G1-G2: -4 |
| Myrelid, 2006189 | Azathioprine  Route: Unknown  Dose: NR | Azathioprine or 6-MP intolerant group | HR QoL (Patients' perceived health assessed by visual analogue scale ) @ 21.3 weeks | Active  No  NA | F: Mean, 65.4 (95% CI, 0 to 99.4) | F: Mean, 55.5 (95% CI, 14.6 to 98.6) P: NS |

6-MP = 6-mercaptopurine; AE = adverse events; CI = confidence interval; F-B = change score; g = grams; G1-G2 = change score in group 1 minus the change score in group 2;

HR QoL = health-related quality of life; IBDQ = Inflammatory Bowel Disease Questionnaire; ITT = intention-to-treat analysis; mg/kg = milligrams per kilogram;

NA = not applicable; NR = not reported; NS = not significant; SD = standard deviation